James Udelson

Summary

Affiliation: Tufts-New England Medical Center
Country: USA

Publications

  1. ncbi request reprint Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure
    Paul J Hauptman
    Division of Cardiology, Saint Louis University School of Medicine, St Louis, Missouri, USA
    Am J Cardiol 98:60L-66L. 2006
  2. ncbi request reprint The historical and conceptual evolution of radionuclide assessment of myocardial viability
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    J Nucl Cardiol 11:318-34. 2004
  3. ncbi request reprint Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, 750 Washington St, Boston, Mass 02111, USA
    Circulation 109:457-64. 2004
  4. ncbi request reprint Ventricular remodeling in heart failure and the effect of beta-blockade
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Cardiol 93:43B-8B. 2004
  5. ncbi request reprint Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 49:2151-9. 2007
  6. ncbi request reprint Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia
    Mihai Gheorghiade
    Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 97:1064-7. 2006
  7. ncbi request reprint Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization
    Leonardo De Luca
    Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy
    Am J Cardiol 96:24L-33L. 2005
  8. doi request reprint Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy
    Iacopo Olivotto
    Regional Referral Center for Myocardial Diseases and Radiology Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
    J Am Coll Cardiol 52:559-66. 2008
  9. ncbi request reprint Gender-based differences in brachial artery flow-mediated vasodilation as an indicator of significant coronary artery disease
    Ayan R Patel
    The Division of Cardiology, Department of Medicine, Tufts New England Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 96:1223-6. 2005
  10. doi request reprint Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy
    Caitlin J Harrigan
    PERFUSE Core Laboratory and Data Coordinating Center, Harvard Medical School, Boston, MA, USA
    Am J Cardiol 101:668-73. 2008

Research Grants

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure
    Paul J Hauptman
    Division of Cardiology, Saint Louis University School of Medicine, St Louis, Missouri, USA
    Am J Cardiol 98:60L-66L. 2006
    ..The background, methods, and statistical approaches used in this trial are reviewed in this article...
  2. ncbi request reprint The historical and conceptual evolution of radionuclide assessment of myocardial viability
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    J Nucl Cardiol 11:318-34. 2004
  3. ncbi request reprint Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, 750 Washington St, Boston, Mass 02111, USA
    Circulation 109:457-64. 2004
    ..Selective agonism of the adenosine A2A receptor should result in a similar degree of coronary vasodilation (and thus similar perfusion images) with fewer side effects...
  4. ncbi request reprint Ventricular remodeling in heart failure and the effect of beta-blockade
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Cardiol 93:43B-8B. 2004
    ..Differences in their effect on remodeling have been recently shown among the beta-blockers. Several studies and a meta-analysis suggest that carvedilol may be more favorable to outcome, having the most effect on LV remodeling...
  5. ncbi request reprint Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 49:2151-9. 2007
    ..This study sought to examine the effects of vasopressin V2 receptor antagonism with tolvaptan on the changes in left ventricular (LV) volumes over time...
  6. ncbi request reprint Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia
    Mihai Gheorghiade
    Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 97:1064-7. 2006
    ..No differences in adverse events were observed between the groups. In conclusion, tolvaptan appears to be more effective than fluid restriction at correcting hyponatremia in hospitalized subjects, without an increase in adverse events...
  7. ncbi request reprint Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization
    Leonardo De Luca
    Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy
    Am J Cardiol 96:24L-33L. 2005
    ..Some AVP receptor antagonists have shown promising results in animal studies and small-scale clinical trials. The purpose of this review was to update the current status of studies with the available AVP antagonists...
  8. doi request reprint Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy
    Iacopo Olivotto
    Regional Referral Center for Myocardial Diseases and Radiology Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
    J Am Coll Cardiol 52:559-66. 2008
    ..Our aim was to assess the distribution and clinical significance of left ventricular (LV) mass in patients with hypertrophic cardiomyopathy (HCM)...
  9. ncbi request reprint Gender-based differences in brachial artery flow-mediated vasodilation as an indicator of significant coronary artery disease
    Ayan R Patel
    The Division of Cardiology, Department of Medicine, Tufts New England Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 96:1223-6. 2005
    ..In studies using FMD to evaluate cardiovascular risk, different standards should be applied for women and men...
  10. doi request reprint Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy
    Caitlin J Harrigan
    PERFUSE Core Laboratory and Data Coordinating Center, Harvard Medical School, Boston, MA, USA
    Am J Cardiol 101:668-73. 2008
    ..The identification of accessory PMs may be useful in planning preoperative strategy...
  11. ncbi request reprint Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy
    Iacopo Olivotto
    Regional Referral Center for Myocardial Diseases, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
    J Am Coll Cardiol 46:480-7. 2005
    ..The goal of this study was to assess gender-related differences in a multicenter population with hypertrophic cardiomyopathy (HCM)...
  12. ncbi request reprint Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy
    Martin S Maron
    Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Am J Cardiol 95:1329-33. 2005
    ..In conclusion, no direct relation was evident between symptoms of heart failure and magnitude of LV wall thickness, with implications for the natural history of HC...
  13. ncbi request reprint Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy
    Kevin M Harris
    Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 E 28th St, Suite 60, Minneapolis, Minnesota 55407, USA
    Circulation 114:216-25. 2006
    ..End stage (ES) is a recognized part of the hypertrophic cardiomyopathy (HCM) disease spectrum. Frequency, clinical profile and course, and treatment strategies in these patients remain incompletely defined...
  14. doi request reprint Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction
    Norman C Wang
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    JAMA 299:2656-66. 2008
    ..Hospitalization for heart failure is associated with high postdischarge mortality and morbidity. The predictive value of the QRS duration during admission for heart failure has not been well studied...
  15. ncbi request reprint Right ventricular involvement in hypertrophic cardiomyopathy
    Martin S Maron
    Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts New England Medical Center, Boston, MA, USA
    Am J Cardiol 100:1293-8. 2007
    ..4, p <0.001). Only 1 (2%) patient with HC had evidence of RV wall fibrosis. In conclusion, morphologic RV abnormalities are present in a substantial proportion of patients with HC...
  16. ncbi request reprint Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial
    Joseph Rossi
    Feinberg School of Medicine Northwestern University, Chicago, Illinois 60611, USA
    Acute Card Care 9:82-6. 2007
    ..Hyponatremia predicts poor outcome in patients with acute heart failure syndromes. This study evaluated the relationship between baseline serum sodium, change in serum sodium, and 60-day mortality in hospitalized heart failure patients...
  17. ncbi request reprint Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial
    Douglas W Losordo
    Feinberg Cardiovascular Research Institute, and Department of Medicine, Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital, Chicago, IL 60611, USA
    Circulation 115:3165-72. 2007
    ..Preclinical studies have indicated that human CD34+ stem cells induce neovascularization in ischemic myocardium, which enhances perfusion and function...
  18. doi request reprint Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy
    Martin S Maron
    Division of Cardiology, Hypertrophic Cardiomyopathy Center, Tufts Medical Center, Boston, Massachussetts 02111, USA
    Circulation 118:1541-9. 2008
    ..This study reports the prevalence, morphology, clinical course, and management of an underrecognized subgroup of HCM patients with left ventricular apical aneurysms...
  19. ncbi request reprint Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 297:1332-43. 2007
    ..Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition...
  20. ncbi request reprint Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
    JAMA 297:1319-31. 2007
    ..Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure...
  21. ncbi request reprint Vascular endothelial dysfunction is associated with reversible myocardial perfusion defects in the absence of obstructive coronary artery disease
    Prem Soman
    Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
    J Nucl Cardiol 13:756-60. 2006
    ..Recent evidence suggests that coronary endothelial dysfunction might play a role in the pathogenesis of these defects...
  22. ncbi request reprint Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction
    Martin S Maron
    Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    Circulation 114:2232-9. 2006
    ..We sought to prospectively define the prevalence, clinical profile, and significance of left ventricular (LV) outflow tract obstruction under resting conditions and with physiological exercise in a large HCM cohort...
  23. ncbi request reprint Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA
    J Card Fail 11:260-9. 2005
    ....
  24. ncbi request reprint Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart
    Richard D Patten
    Molecular Cardiology Research Institute, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 45:1419-24. 2005
    ..We examined the effect of mechanical unloading with ventricular assist device (VAD) therapy on myocardial inducible nitric oxide synthase (iNOS) expression and cardiomyocyte apoptosis in patients with end-stage heart failure (HF)...
  25. ncbi request reprint Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial
    Michael Simons
    Section of Cardiology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Circulation 105:788-93. 2002
    ..We conducted the FGF Initiating RevaScularization Trial (FIRST) to evaluate further the efficacy and safety of recombinant FGF2 (rFGF2)...
  26. ncbi request reprint Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis
    Kevin C Allman
    Concord Hospital, Concord NSW, Australia
    J Am Coll Cardiol 39:1151-8. 2002
    ....
  27. ncbi request reprint Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials
    Inder S Anand
    Division of Cardiology, University of Minnesota Medical School and Veterans Administration Medical Center, Minneapolis, MN 55417, USA
    J Card Fail 8:S452-64. 2002
    ..Thus, to study the process of remodeling in practice and in clinical trials, we have relied on assessments and measurements derived from cardiac imaging tests...
  28. ncbi request reprint Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
    J Card Fail 8:S465-71. 2002
    ..After any insult to the left ventricle resulting in diminished systolic performance and stroke volume, a series of histopathologic changes in the myocardium and structural changes in the LV chamber occurs over time...
  29. ncbi request reprint New concepts in post-infarction ventricular remodeling
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Rev Cardiovasc Med 4:S3-12. 2003
    ..It is also demonstrated that drug therapies that slow or reverse the remodeling process appear to have favorable natural history effects in the short term as well as during long-term therapy...
  30. ncbi request reprint Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients
    Ayan R Patel
    Division of Cardiology Department of Medicine, Molecular Cardiology Research Institute, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Am J Cardiol 91:897-9. 2003
  31. ncbi request reprint Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude
    Jeffrey T Kuvin
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center Hospitals, Tufts University School of Medicine, Boston, MA 02111, USA
    Am Heart J 146:168-74. 2003
    ..We evaluated the relationship between changes in PWA of the finger and peripheral endothelial function...
  32. ncbi request reprint Quantitative instruments for predicting risk ... and benefit
    James E Udelson
    J Am Coll Cardiol 45:730-2. 2005
  33. ncbi request reprint Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial
    Carey Kimmelstiel
    Division of Cardiology, Tufts New England Medical Center, and Tufts University School of Medicine, Boston, Mass 02111, USA
    Circulation 110:1450-5. 2004
    ..Most of these studies are limited by small sample size; absence of concurrent, randomized controls; limited follow-up; restriction to urban academic centers; and low baseline use of effective medications...
  34. ncbi request reprint A head-to-head comparison of infusion and bolus doses of adenosine for stress myocardial contrast echocardiography
    Hans Joachim Nesser
    IInd Department of Medicine, Cardiology, KH der Elisabethinen Hospital, Linz, Austria
    Echocardiography 23:483-9. 2006
    ..This study was a head-to-head, intraindividual comparison of the diagnostic accuracy and side effect profile of bolus and infusion administration of adenosine for stress myocardial contrast echocardiography (MCE)...
  35. ncbi request reprint Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial
    James E Udelson
    Division of Clinical Care Research, Tufts New England Medical Center, 750 Washington St, Box 70, Boston, MA 02111, USA
    JAMA 288:2693-700. 2002
    ....
  36. ncbi request reprint Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for management
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Mass 02111, USA
    J Nucl Cardiol 9:40S-52S. 2002
  37. ncbi request reprint Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia
    Vasken Dilsizian
    Division of Nuclear Medicine, University of Maryland Hospital and School of Medicine, Baltimore, MD 21201 1595, USA
    Circulation 112:2169-74. 2005
    ..We hypothesized that a branched-chain fatty acid, beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid (BMIPP), might identify the presence of myocardial ischemia late after demand ischemia at rest up to 30 hours later...
  38. doi request reprint Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance
    A Selcuk Adabag
    Division of Cardiology, Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA
    J Am Coll Cardiol 51:1369-74. 2008
    ..Our aim was to determine whether myocardial fibrosis, detected by cardiovascular magnetic resonance (CMR), represents an arrhythmogenic substrate in hypertrophic cardiomyopathy (HCM)...
  39. doi request reprint Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia
    John J Finley
    Division of Cardiology and Department of Medicine, Tufts Medical Center, Boston, Mass 02111, USA
    Circulation 118:410-21. 2008
  40. ncbi request reprint Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome
    Barry J Maron
    J Am Coll Cardiol 45:1340-5. 2005
  41. doi request reprint Assessment and key targets for therapy in the post-myocardial infarction patient with left ventricular dysfunction
    James D Flaherty
    Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Am J Cardiol 102:5G-12G. 2008
    ..This review describes the current modalities for assessing the key pathophysiologic targets in post-MI patients with LVD and the effects of systemic factors on cardiac disease severity...
  42. ncbi request reprint Prevention and reversal of left ventricular remodeling: summation
    Marvin A Konstam
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Card Fail 8:S506-11. 2002
  43. ncbi request reprint Future directions of myocardial fatty acid imaging
    Christopher J Pastore
    Division of Cardiology, Department of Medicine, Tufts New England Medical Center, Boston, MA 02111, USA
    J Nucl Cardiol 14:S153-63. 2007
  44. ncbi request reprint Screening the population for coronary artery disease: is it like screening for cancer?
    Prem Soman
    J Nucl Cardiol 12:145-7. 2005
  45. ncbi request reprint ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guideli
    Francis J Klocke
    Circulation 108:1404-18. 2003
  46. ncbi request reprint Ventricular remodeling in heart failure: a credible surrogate endpoint
    Marvin A Konstam
    J Card Fail 9:350-3. 2003
  47. ncbi request reprint Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy
    Barry J Maron
    The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 E 28th St, Suite 60, Minneapolis, Minn 55407, USA
    Circulation 107:2872-5. 2003
  48. ncbi request reprint MIBG imaging for selecting heart failure patients for defibrillator therapy: a first step
    Colin D Shafer
    J Nucl Cardiol 10:208-10. 2003
  49. ncbi request reprint Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction
    Gregg C Fonarow
    Rev Cardiovasc Med 4:S54-9. 2003
  50. ncbi request reprint The price for probability: Comparing the costs of diagnostic testing strategies
    Prem Soman
    J Nucl Cardiol 14:142-4. 2007
  51. ncbi request reprint Hyponatremia in patients with heart failure
    Leonardo De Luca
    Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy
    Am J Cardiol 96:19L-23L. 2005
    ..Recent studies have suggested that correction of hyponatremia may be associated with improved survival. This hypothesis is currently being studied in large prospective randomized clinical trials...
  52. ncbi request reprint Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure
    Olaf Hedrich
    Tufts New England Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    Heart Fail Clin 1:103-27. 2005

Research Grants7

  1. LV Function Assessment Core Lab for IMMEDIATE Trial
    James Udelson; Fiscal Year: 2006
    ..These data Will provide robust information with sufficient power to test the concepts in Hypothesis H9 of the parent trial and provide substantial insights into the mechanism of GIK effect. ..
  2. Myocardial Viability and Remodeling in the OAT
    James Udelson; Fiscal Year: 2007
    ..OAT-NUC is the only viability ancillary study of OAT, and thus serves a critical need in assessing potential mechanisms of the findings in OAT. ..